VA will offer coverage of Alzheimer’s drug after Medicare passes

THe Veterans Health Administration announced that it will pay large amounts for the cost of a new device. Alzheimer’s drug after Medicare It had not been announced.

After going through an expedited pathway by the Food and Drug Administration, Leqembi was approved last month. It is a $26,500 per-year drug. Veteran with Alzheimer’s disease in the early stages can use the drug manufactured by Eisai, Biogen. It can moderately slow cognitive decline and reduce the amount of protein amyloid.

RECKONING THE GOP WITH ENTITLEMENT PROGRAMS

Last month, the Centers for Medicare & Medicaid Services denied unrestricted coverage to the Alzheimer’s Association. They stated that they needed more data before making a decision.

The drug was found to be safe and effective in the tests. slowed cognitive decline Alzheimer’s disease by 27% when compared to a placebo. The first time this has been done, the results showed that patients could benefit from reducing amyloid.

Leqembi targets amyloid plaque that has built up in the brain. Although it can reduce the buildup, it cannot cure Alzheimer’s. Hill. A study found that the drug had serious side effects including brain swelling, bleeding, and even death.

Due to the drug’s high cost and restricted coverage, seniors without Medicare assistance would not be able afford it. July 6th is the FDA deadline for approval. The FDA deadline for approval is July 6.

Veterans Affairs will now cover Leqembi for the moment, making it the largest major insurer to cover the drug.

Aduhelm was an anti-amyloid drug that Eisai and Biogen had previously developed, which was nearly twice the price of Leqembi at first.

CLICK HERE FOR MORE INFORMATION FROM THE WASHINGTON XAMINER

Aduhelm decreased amyloid plaque but The situation did not improve Clinical outcomes in Alzheimer’s patients were not favorable, so drug development was halted in 2012.

Aduhelm was denied coverage by Medicare and Veterans Affairs due to safety and efficacy issues.